HER2-positive breast cancer (BC) constitutes a molecular subtype of the disease with an aggressive biologic behavior. Trastuzumab revolutionized the treatment of this disease, changing its natural history. Lapatinib is active in the metastatic setting, approved for patients who were pretreated with trastuzumab. However, resistance to anti-HER2 agents is a major clinical issue, occurring in both early-stage and advanced disease, and new treatment options are clearly needed. An abundance of HER2-targeted agents are being clinically developed: monoclonal antibodies, small molecule inhibitors, and antibody drug conjugates (ADC). Combining HER2-targeted agents in regimens of dual HER2 blockade has already reached clinical practice in the metastatic setting, confirming the preclinical efficacy of enhanced HER2 inhibition. Promising results have been generated in the neoadjuvant setting, and large randomized trials are seeking evidence for dual HER2 blockade in the adjuvant setting. ADC represent another hope for improved treatment outcomes of HER2-positive BC, as exemplified by the positive results of clinical trials employing trastuzumab-DM1 (trastuzumab emtansine, T-DM1). Moreover, an understanding of the molecular mechanisms mediating resistance to HER2 blockade has opened new therapeutic avenues, with several targeted agents entering clinical trials. This paper presents the clinical data of the HER2-targeted agents under development, as well as an overview of the biologic rationale for the development of agents aimed at circumventing anti-HER2 resistance.
pidermal growth factor receptor 2 (EGFR2; HER2/neu, ErbB2), a type II transmembrane receptor, constitutes a well-studied oncogene, mediating a plethora of oncogenic effects, through interlinked activation of PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways. 1 Amplifıcation of the gene and/or protein overexpression is detected in approximately 20% of patients with BC and confers an aggressive biologic phenotype, resulting in poor clinical outcome. 2 The development of trastuzumab, a humanized monoclonal antibody targeting domain IV of HER2, represents the fırst signifıcant milestone in the development of anti-HER2-targeted agents. Trastuzumab is the mainstay of HER2 blockade in all stages of HER2-positive disease, changing its natural history. 3 Lapatinib constitutes another important development in the arena of HER2-blocking agents, being a dual EGFR/HER2 reversible tyrosine kinase inhibitor (TKI), currently approved in combination with either capecitabine or letrozole for patients with HER2-positive metastatic BC (MBC). 3 Despite the antitumor activity of those two agents, a subset of patients with early stage HER2-positive BC unfortunately relapses; in the metastatic setting, primary or secondary resistance develops inevitably. This clinical reality mandates new treatment options, with a plethora of HER2-targeted agents showing different mechanisms of action (Table 1) currently under clinical development (Tables 2 and 3) . One promising approach is dual HER2-blockade. Combined administration of different HER2-targeted agents shows heightened antitumor activity, based on the complementarity of their mechanisms of action, leading to more complete HER2 blockade. This strategy has already reached clinical practice in the metastatic setting and has demonstrated higher rates of pathologic complete response (pCR) in the neoadjuvant setting (Fig. 1) . A second approach is the development of anti-HER2 ADC, as exemplifıed by the development of trastuzumab-DM1. A third approach, which is earlier in clinical development, derives from the elucidation of the molecular mechanisms mediating resistance to HER2 blockade. This strategy combines HER2 blockade with a compound blocking a molecular mediator of anti-HER2 resistance, with the goal of "(re)sensitizing" HER2-positive BC cells to HER2 inhibition (Table 4) .
TRASTUZUMAB AND LAPATINIB
Trastuzumab and lapatinib exhibit complementary mechanisms of HER2 blockade (Table 1) , and preclinical studies have shown a synergy between these two agents: increased antibody-dependent cellular cytotoxicity (ADCC) and enhanced induction of apoptosis in xenograft tumor models have been reported. 4, 5 In the metastatic setting, the combination of trastuzumab and lapatinib was assessed in the phase III EGF104900 study, which randomly selected patients who were pretreated with trastuzumab to receive lapatinib alone or lapatinib combined with trastuzumab. The dual HER2 blockade resulted in a signifıcant prolongation of median progression-free survival (mPFS; 11.1 week vs. 8.1 week, p ϭ 0.011) and of overall survival (OS; 14 months vs. 9.5 months, p ϭ 0.026), despite signifıcant cross-over (52%). 6 The toxicity of the lapatinib/ trastuzumab regimen was acceptable, with increased rates of grade 1 and 2 diarrhea (p ϭ 0.03) and a higher frequency of 20% or greater reduction in the left ventricular ejection fraction (LVEF; 5.4 vs. 2.1%), as compared to lapatinib monotherapy.
In the neoadjuvant setting, Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial (Neo-ALTTO) was a phase III study that randomly selected 455 patients with HER2-positive operable BC to receive lapatinib, trastuzumab, or their combination for a total of 6 weeks. After this period, the assigned HER2-blocking strategy was combined with paclitaxel for further 12 weeks. The dual HER2-blockade resulted in a signifıcant improvement in the pCR rate, outperforming the trastuzumab and lapatinib arms (pCR 51.3% vs. 29.5% vs. 24.7%, respectively; p ϭ 0.0001 for the trastuzumab-lapatinib arm versus trastuzumab alone). 7 The pCR rates were more pronounced in the patients with hormone receptor-negative disease. No major cardiac dysfunction was noted, and the lapatinib-containing arms were associated with more grade 3 and 4 adverse events (AEs) and higher rates of treatment discontinuation.
Similar results were reported by the Chemotherapy, Herceptin, and Lapatinib in Operable Breast Cancer study (CHER-LOB). 8 In this phase II study, 121 patients with operable HER2-positive BC were allocated to receive neoadjuvant taxane-anthracycline chemotherapy combined with lapatinib (Arm A), trastuzumab (Arm B), or lapatinib plus trastuzumab (Arm C). The lapatinib/trastuzumab combination was associated with higher pCR rates (48%) than the lapatinib (pCR 28%) and trastuzumab arms (pCR 32%). A third neoadjuvant study-the Translational Breast Cancer Research Consortium (TBCRC 006)-assessed the lapatinib/ trastuzumab combination in a chemotherapy-free regimen administered for 12 weeks (plus hormone therapy for patients with hormone receptor-positive BC). 9 In this phase II study, 64 patients diagnosed with HER2-positive BC with a median tumor size of 6 cm achieved pCR in 28% overall; once again hormone receptor negativity was associated with increased pCR rates (42% vs. 21% for patients with estrogen receptor (ER)-negative and ER-positive BC, respectively).
The combined administration of trastuzumab and lapatinib is currently under clinical investigation in the adjuvant setting. The ALTTO study (NCT00490139)-a phase III study with a completed accrual exceeding 8,300 patientscompared the activity of lapatinib monotherapy, trastuzumab monotherapy, trastuzumab followed by lapatinib, and trastuzumab concomitantly with lapatinib in patients with early-stage HER2-positive BC. The primary endpoint of
KEY POINTS
⅐ Despite the efficacy of trastuzumab in the adjuvant setting, there is a subset of patients developing recurrence of the disease. In the metastatic setting, resistance inevitably occurs. ⅐ Currently, an abundance of HER2-targeted agents are under clinical development, namely: monoclonal antibodies, small molecule inhibitors, and antibody drug conjugates. ⅐ The concept of dual HER2 blockade has already made its way into clinical practice with the approval of pertuzumab in combination with trastuzumab and docetaxel in the first line of metastatic disease. ⅐ Trastuzumab-DM1, an anti-HER2 antibody drug conjugate, is an active agent currently in advanced clinical testing. ⅐ Several molecular components of resistance mechanisms to HER2 blockade are being pursued as therapeutic targets with experimental compounds under development. 
FIG 1. pCR rates in trials assessing dual HER2 blockade.
Abbreviations: pCR, pathologic complete response; Anthra, anthracycline; C, carboplatin; D, docetaxel; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; L, lapatinib; P, pertuzumab; pac, paclitaxel; T, trastuzumab; tax, taxane. this study is the comparison of disease-free survival (DFS) between the trastuzumab-alone and the combination arms. Importantly, the fırst interim analysis of the ALTTO study resulted in the closure of the lapatinib-alone arm, since it was deemed unlikely to cross the boundary of noninferiority. 10
PERTUZUMAB
Pertuzumab is a humanized monoclonal antibody, binding to the dimerization domain II of HER2, thus blocking ligandinduced HER2/HER3 heterodimerization. 11 This dimerization represents an important molecular event driving malignant progression of HER2-positive BC cells through its potent ability to activate the PI3K/Akt/mTOR signaling pathway. Preclinical evidence showed a synergistic effect of pertuzumab combined with trastuzumab, so that clinical trials assessing this dual HER2 blockade strategy followed. 12 Several phase I studies have been conducted in the metastatic setting, assessing pertuzumab either as monotherapy or in combination with cytotoxic agents. A small phase II trial assessed the combination of pertuzumab and trastuzumab in 11 patients who were pretreated with trastuzumab and had had HER2-positive MBC. 13 An overall response rate (ORR) of 18% and a clinical benefıt rate (CBR) of 44.5% were reported; however, the accrual to this study was prematurely terminated because of cardiac toxicities. Six patients developed an LVEF decrease, with two exceeding a reduction of 15%, and one of them developed symptomatic congestive heart failure. Another phase II study assessed the combination of pertuzumab plus continued trastuzumab therapy in 66 patients with HER2-positive MBC progressing on trastuzumab-based therapy, showing promising antitumor activity: ORR reached 24.2% and CBR was 50%, with fıve patients achieving a complete response (CR; 7.6%) and 11 patients achieving a partial response (PR; 16.7%). 14 The cardiac safety profıle was favorable in this trial in comparison to the smaller one, with no patient withdrawing from the study as a result of cardiac toxicity. The cardiac safety of pertuzumab was proved by a pooled analysis study of 598 patients who received pertuzumab either as monotherapy or in combination with other compounds, showing that pertuzumab did not result in a notable increase in cardiac-related side effects. 15 Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA; NCT00567190) is a randomized, phase III clinical trial that assigned 808 previously untreated patients with HER2-positive MBC to receive either docetaxel plus trastuzumab or the same regimen combined with pertuzumab. 16 The dual HER2 blockade resulted in a signifıcant prolongation of independently assessed progression-free survival (PFS), the trial's primary endpoint, as compared with the standard of care (mPFS 18.5 vs. 12.4 months, HR 0.65; 95% CI, 0.51 to 0.75, p Ͻ 0.001). An interim analysis of OS showed a trend favoring the pertuzumab-containing arm, which did not cross the stringent predefıned p value (HR 0.64; 95% CI, 0.47 to 0.88, p ϭ 0.005), with few reported OS events. A second OS analysis performed with 69% of planned events for the fınal analysis showed a statistical signifıcance favoring the pertuzumab-containing arm (mOS not reached compared with 37.6 months in the placebo arm; HR 0.66; 95% CI, 0.52-0.84, p ϭ 0.0008). 17 ORR reached 69.3% in the control group and 80.2% in the pertuzumab group. Of note, only 10% of the patients enrolled in CLEOPATRA had received trastuzumab as part of a (neo)adjuvant regimen. However, exploratory analysis revealed no difference in effıcacy of the pertuzumab-containing arm according to prior trastuzumab exposure. In terms of toxicity, diarrhea, rash, mucosal inflammation, febrile neutropenia, and dry skin of any grade were reported more frequently in the pertuzumabcontaining arm. The cardiac safety profıles between the two arms were comparable, with left ventricular systolic dysfunction grade 3 and greater reported in 2.8% of the patients in the control group and in 1.2% of the patients in the pertuzumabgroup. On the basis of these results, pertuzumab is approved for use in the fırst-line setting of HER2-positive MBC, in combination with trastuzumab and docetaxel.
Pertuzumab has been also assessed in combination with trastuzumab in the neoadjuvant setting. The phase II study Neoadjuvant Study of Pertuzumab and Herceptin in Early Regimen Evaluation (NeoSphere; NCT00545688) randomly selected 417 patients to receive four cycles (12 weeks) of one of the following four preoperative regimens: trastuzumab plus pertuzumab plus docetaxel; trastuzumab plus docetaxel; pertuzumab plus docetaxel; or trastuzumab plus pertuzumab. 18 The pCR rates, the primary endpoint of this trial, were 45.8% for the triplet, 29% for the trastuzumab plus docetaxel, 24% for pertuzumab plus docetaxel, and 16.8% for the chemotherapy-free pertuzumab plus trastuzumab combination. In all arms of the study, the rates of pCR were higher in the subgroup of women with ER-negative disease, with a pCR rate of 27.3% for women receiving the chemotherapy-free combination of pertuzumab plus trastuzumab. Importantly, this suggests that a proportion of women with HER2-positive disease could be cured without cytotoxic chemotherapy. TRYPHAENA (NCT00976989) is another phase II study that has been reported in the neoadjuvant setting. It randomly selected 225 patients to receive one of the three following arms: pertuzumab plus trastuzumab given concurrently with an anthracycline-taxane regimen (5-fluorouracil, epirubicin, cyclophosphamide [FEC] followed by docetaxel) or the dual HER2-combination given sequentially to FEC, but concurrently with docetaxel, or this anti-HER2 doublet given concurrently with carboplatin and docetaxel. 19 The primary endpoint of this trial was cardiac safety, which was comparable across all three tested arms. pCR was 61.6% for arm 1, 57% for arm 2, and 66.2% in arm 3, with ER negativity associated with higher pCR rates (79.4%, 65.0%, and 83.8% for arms 1, 2, and 3, respectively).
The aforementioned clinical effıcacy data led to the development of a phase III prospective multicenter clinical trial assessing the effıcacy of pertuzumab in the adjuvant setting: Adjuvant Pertuzumab and Herceptin in Initial Therapy of Breast Cancer, BIG 4 -11 (APHINITY; NCT01358877) is an ongoing international collaborative study, aiming to ran-domly selected approximately 4,800 patients with early-stage HER2-positive BC to receive either trastuzumab or trastuzumab with pertuzumab in conjunction with cytotoxic chemotherapy.
HER FAMILY SMALL MOLECULE INHIBITORS
Neratinib is an oral, irreversible pan-HER TKI of EGFR/ HER1, HER2, and HER4 under clinical development. A phase II study assessed neratinib in patients with HER2-positive MBC who had either previously received trastuzumab (66 patients) or not (70 patients). 20 Neratinib showed substantial antitumor activity with the 16-week PFS rates being 59% for patients who has been pretreated with trastuzumab and 78% for patients who were trastuzumab-naive and median PFS reaching 22.3 and 39.6 weeks, respectively. The most common AEs were diarrhea, which was the most frequent grade 3 to 4 AE, nausea, vomiting, and fatigue. No neratinib-related cardiotoxicity of grade 3 or 4 was reported. Neratinib has also been evaluated in combination with trastuzumab in a phase I/II study of 45 patients with trastuzumab-pretreated HER2-positive MBC. 21 Promising antitumor activity was noted, with a 16-week PFS rate of 47% and a mPFS of 19 weeks. No new toxicity signals were observed. Preliminary results of a phase I study assessing a triplet of weekly paclitaxel with neratinib and trastuzumab in women with heavily pretreated HER2-positive MBC have been presented; out of 10 patients for whom effıcacy data were available, there was one CR and three PR, with diarrhea being the most frequent grade 3 and 4 AE. 22 Another phase I study assessed the feasibility of neratinib combined with everolimus, with signs of antitumor activity: out of eight patients with heavily pretreated HER2-positive MBC, four showed a PR and one had SD for an RR of 67%. 23 A randomized phase II study compared neratinib with lapatinib plus capecitabine in the second line of metastatic disease. Neratinib demonstrated high antitumor activity (ORR 29%); however, it was inferior to the lapatinib/capecitabine arm in terms of mPFS, the primary endpoint of the trial (mPFS 4.5 vs. 6.8 months, HR 1.3; 95% CI, 1.0 to 1.8). 24 A phase III study is currently underway evaluating neratinib in patients with early-stage HER2-postive BC after completion of standard trastuzumab based adjuvant chemotherapy (NCT00878709).
Afatinib is another promising orally available irreversible pan-HER TKI under clinical development. A phase II single-arm study assessed its activity in 41 patients with trastuzumab-pretreated HER2-positive MBC, with a median of three prior chemotherapy lines (range, 0 -15). 25 Promising clinical activity was shown, with four patients (10%) having PR, 15 patients (37%) having stable disease as best response and mPFS reaching 15.1 week (95% CI, 8.1 to 16.7 weeks). The most common grade 3 AEs were diarrhea and rash. Currently, there are ongoing trials assessing afatinib in HER2-positive BC (Table 3) , with a phase III trial (LUX-Breast 1, NCT01125566) randomly selecting patients with HER2-positive MBC to receive afatinib plus vinorelbine or trastuzumab plus vinorelbine as fırst-or second-line treatment.
T-DM1
T-DM1 is an ADC consisting of DM1, a maytansinoid antimicrotubule agent, bound to trastuzumab through nonreducible thioether bonds. T-DM1 delivers this highly potent cytotoxic agent specifıcally to HER2-expressing cells. Once T-DM1 binds to HER2 on the cell surface, the T-DM1-HER2 complex is internalized and the antibody component is proteolytically degraded, releasing the DM1 into the cytoplasm. 26 Importantly, T-DM1 retains the biologic activity of trastuzumab (i.e., HER2 signaling blockade and induction of ADCC). 27 These properties provided the biologic rationale for testing T-DM1 in the setting of HER2-positive BC.
A phase I study conducted in 24 patients with advanced, heavily pretreated (median, four prior chemotherapeutic agents for metastatic disease) HER2-positive BC assessed the safety and tolerability of T-DM1 in three-weekly administered ascending doses. 28 The maximum tolerated dose (MTD) of T-DM1 was 3.6 mg/kg, with transient thrombocytopenia being a dose-limiting toxicity. The toxicity profıle was favorable with common drug-related AEs being grade 2 and lower thrombocytopenia, elevated transaminases, fatigue, nausea, and anemia. Preliminary signs of antitumor activity were generated, with a CBR (defıned as the objective response plus stable disease at six months) among the 15 patients treated at the MTD reaching 73%. Two consecutive phase II single-arm studies of T-DM1 in HER2-positive MBC have been reported. The fırst one reported an ORR of 25.9% (95% CI, 18.4% to 34.4%) by independent assessment among 112 heavily pretreated patients. 29 There were not suffıcient events to reach median duration of response, and mPFS was 4.6 months (95% CI, 3.9 to 8.6 months). Another phase II study assessed T-DM1 monotherapy in 110 patients with HER2-positive MBC, who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine (median, seven prior agents for metastatic disease). 30 The ORR was 34.5% (95% CI, 26.1% to 43.9%), the CBR was 48.2% (95% CI, 38.8% to 57.9%), mPFS was 6.9 months (95% CI, 4.2 to 8.4 months), and median duration of response was 7.2 months (95% CI, 4.6 months to not estimable). Both studies showed a favorable toxicity profıle, with most AEs being grade 1 to 2; the most frequent grade 3 and lower AEs were thrombocytopenia and fatigue.
The results of a randomized phase II trial have been also reported; that study randomly selected 137 previously untreated patients to receive either T-DM1 or trastuzumab with docetaxel. 31 T-DM1 resulted in a signifıcant prolongation of mPFS as compared to the comparator arm (14.2 vs. 9.2 months, p ϭ 0.035), whereas no signifıcant differences in ORR (64% for T-DM1 vs. 58% in the control arm) or in CBR (75% for T-DM1 vs. 81% in the control arm) were found. The toxicity profıle of T-DM1 compared favorably with standard treatment, with the rates of grade 3 or 4 neutropenia being 5.8% and 61% and the rates of alopecia being 4.3% and 67%, respectively.
Positive results confırming the antitumor activity of T-DM1 in the setting of HER2-positive MBC were recently reported from the phase III randomized trial EMILIA (NCT00829166). 32 This study randomly assigned 991 patients, previously treated with trastuzumab and a taxane, to receive T-DM1 or lapatinib plus capecitabine. The study met its primary endpoint, with T-DM1 resulting in a signifıcant prolongation of mPFS as compared with the lapatinib plus capecitabine arm (9.6 vs. 6.4 months, HR 0.65; 95% CI, 0.55 to 0.77, p Ͻ 0.001), assessed by independent review. The ORR also favored the T-DM1 arm (43.6% vs. 30.8%, p Ͻ 0.001), as did the median duration of response (12.6 months vs. 6.5 months). The median OS (mOS) at the second interim analysis crossed the stopping boundary for effıcacy (30.9 vs. 25.1 month, HR 0.68; 95% CI, 0.55 to 0.85, p Ͻ 0.001) favoring the T-DM1 arm. In terms of toxicity, rates of grade 3 or 4 AEs were lower for T-DM1 overall (41% vs. 57%). T-DM1 was associated with higher incidences of thrombocytopenia and increased liver enzyme levels and lower incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysthesia compared with that for lapatinib plus capecitabine.
Although the results of the EMILIA study provide solid evidence for T-DM1 as the treatment of choice in the secondline setting of HER2-positive MBC, another phase III randomized trial termed MARIANNE (NCT01120184) is seeking evidence to support the use of T-DM1 in the fırst-line setting. With 1,092 enrolled patients, MARIANNE will compare the effıcacy of T-DM1 plus pertuzumab, T-DM1 plus placebo, and the combination of trastuzumab plus a taxane. A third phase III study, TH3RESA (NCT01419197), is evaluating T-DM1 in the third or later line of therapy. In this study, patients with HER2-positive MBC who previously have received trastuzumab, lapatinib, and chemotherapy are randomly selected to receive T-DM1 or physician's choice of therapy. Other ongoing phase II trials are currently exploring the feasibility and/or antitumor potency of T-DM1 in the adjuvant (NCT01196052) and neoadjuvant setting (NCT01745965) of HER2-positive BC.
Pi3k/Akt/mTOR BLOCKING AGENTS
PI3K/Akt/mTOR represents an intracellular signal transduction pathway commonly deregulated in the setting of BC and potentially mediating resistance to anti-HER2-blocking agents. 33 To date, rapalogs represent the most clinically advanced agents targeting this signaling pathway. A phase I study assessed the triple combination of everolimus with paclitaxel and trastuzumab administered weekly in 33 patients with heavily pretreated (median of two lines of chemotherapy in metastatic setting, range, 0 to 17 lines) HER2-positive MBC. 34 Encouraging antitumor activity was reported, with an overall disease control rate 6 months or fewer of 74% and mPFS reaching 34 weeks (95% CI, 29.1 to 40.7 weeks). Grade 3 to 4 neutropenia was the most common toxicity observed (17 patients; 52%). Another phase I study evaluated a regimen of everolimus combined with vinorelbine and trastuzumab in a similar population of 47 patients, with the ORR reaching 19.1%, disease control rate 6 months or fewer of 83% and mPFS reaching 30.7 weeks (95% CI, 28 to 44.9 weeks). 35 Neutropenia (92%) and stomatitis (70%) of any grade were the most common AEs. Results of the dual combination of everolimus with trastuzumab in the metastatic setting have been reported from a pooled analysis (47 patients) of two phase I/II studies conducted concurrently: a CBR of 34% and a mPFS of 4.1 month were reported with fatigue, infection, and mucositis being the most frequent AEs. 36 Currently, there are two ongoing phase III trials of everolimus in the setting of HER2-positive MBC: BOLERO-1 (NCT00876395) assesses the triplet of everolimus, trastuzumab, and paclitaxel as fırst-line regimen, and BOLERO-3 (NCT01007942) assesses the addition of vinorelbine to the two targeted agents in patients previously treated with patients. Importantly, the clinical activity of rapalogs is dampened by their mode of molecular action, which is restricted to mTORC1 inhibition, whereas mTORC2 remains unaffected. 37 To overcome this innate limitation, there are currently many targeted agents blocking different molecular components of the PI3K/Akt/mTOR signaling pathway under development in HER2-positive BC, namely pan-PI3K, PI3K isoform-selective, mTORC1/2 selective, dual PI3K/ mTOR, and Akt inhibitors. 38 
OTHER EXPLORATORY ANTI-HER2-BLOCKING STRATEGIES
Understanding the molecular biology of HER2-positive BC coupled with the elucidation of the molecular mechanisms mediating resistance to HER2 blockade can lead to the development of effective targeted agents. Ongoing trials combining HER2-targeted agents with compounds blocking other signaling pathways hold the promise to further improve the clinical outcome of patients with HER2-positive BC. A potentially promising approach appears to be the combination of HER2 blockade with insulin growth factor receptor 1 (IGF-1R)-blocking agents. A bidirectional crosstalk of HER2 and IGF-1R is well documented, with IGF-1R inhibition restoring sensitivity to trastuzumab in preclinical models. 39, 40 Clinical trials evaluating this hypothesis are currently ongoing. Another rational combination is the blockade of HER2 and SRC. SRC is a nonreceptor tyrosine kinase that was recently shown to function as a common node downstream of multiple trastuzumab-resistance mechanisms, both acquired and de novo. 41 Blocking SRC in combination with trastuzumab showed a heightened synergistic antitumor effıcacy in trastuzumab-resistant tumors in vivo, underlining the potential clinical usefulness of this approach. HER3, as already highlighted preclinically, is another rational molecular target in the setting of HER2-posititve BC. HER3 is a potent activator of PI3K/Akt signaling pathway that has been demonstrated to be upregulated on HER2 blockade. 42 Importantly, a recent report suggested that dual HER2-blockade in HER2-positive BC cells does not completely abrogate HER3 function, so that the addition of a HER3-targeting monoclonal antibody, with the dual combinations of either trastuzumab/pertuzumab or trastuzumab/ lapatinib, led to increased antitumor activity. 43 
CONCLUSION
The aforementioned data underline the antitumor potency of newly developed HER2-blocking agents against HER2-positive BC. Dual HER2 blockade has resulted in clinical successes in both the neoadjuvant (Fig. 1) and metastatic setting. The development of anti-HER2 ADCs promises further treatment options for these patients, achieving selected delivery of potent chemotherapy coupled with HER2 inhibition. Further treatment options could rise from the dissection of the molecular mechanisms mediating resistance to HER2 blockade. Nevertheless, many questions need to be answered: how can we better select the optimal HER2 blockade strategy for the individual patient? Clearly, to answer this question, robust predictive biomarkers are urgently needed. To the present day, only HER2 remains a suitable biomarker for therapeutic decisions about HER2 blockade, as was exemplifıed by the failure of the recent biomarker analysis of the CLEOPATRA study to identify additional predictive biomarkers. 44 How can we identify those patients who can be effectively treated with HER2 blockade without the addition of cytotoxic chemotherapy? Recent fındings indicate that FDG-PET/CT can serve as a valuable tool to this end. The Neo-ALTTO PET study assessed whether metabolic response with anti-HER2 therapies could predict pCR at the time of surgery; pCR rates were twice as high in patients who were FDG-PET/CT responders (using European Organisation for Research and Treatment of Cancer criteria 45 ) compared with nonresponders (41% vs. 21% with FDG-PET/CT after 2 weeks of chemotherapy-free HER2 blockade). 46 Building on these promising results, the Breast International Group (BIG) is planning to launch the I-Integrating Imaging to De-escalate Therapy in HER2-positive breast Cancer Management (DREAM) trial, aiming to defıne the most effective HER2-targeting strategy and identify early on the group of patients who could potentially be spared systemic chemotherapy. What is the optimal sequencing of treatment among the variety of treatment options that are being constantly added in our therapeutic armamentarium (Table 5) ? Is it possible to further improve the antitumor effıcacy of dual HER2 blockade regimens by either HER2 blockade triplets or through the addition of other compounds targeting anti-HER2-resistance mechanisms? Lastly, will we identify more effective anti-HER2 adjuvant regimens with acceptable toxicity? Moreover, in a fınancially constrained environment, issues of increasing costs for the national health care systems are of concern. These questions can be answered through properly conducted collaborative clinical trials. The near future is promising for major leaps forward toward more effective treatment of HER2-positive BC.
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